Skip to main content

Table 1 Baseline characteristics of trial population

From: Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial

  Liraglutide (n = 23) Placebo (n = 26)
Demographics
 Age in years  (SD) 60 (6) 59 (7)
 Male 14 (61%) 15 (58%)
 Diabetes duration in years (SD) 11 (6) 11 (7)
 Diabetes complications
  Retinopathy, n 4 (17%) 2 (8%)
  Nephropathy, n 2 (9%) 11 (42%)
  Neuropathy 10 (44%) 7 (27%)
  Macrovasculara 2 (9%) 0 (0%)
Clinical parameters
 Weight in kg (SD) 98 (14) 94 (13)
 Body-mass index in kg/m2 (SD) 32.6 (4.4) 31.6 (3.4)
 Systolic blood pressure in mmHg (SD) 141 (14) 141 (15)
 Diastolic blood pressure in mmHg (SD) 86 (6) 87 (11)
 Glycated haemoglobin A1c in % (SD) 8.4 (1.1) 8.2 (1.0)
 Glycated haemoglobin A1c in mmol/mol (SD) 67 (12) 65 (10)
 Serum creatinine in μmol/L (SD) 73 (19) 68 (17)
 Urinary albumin/creatinine ratio in mmol/μg (SD) 1.0 (1.3) 5.0 (8.9)
 Triglycerides in mmol/L (SD) 2.2 (1.5) 2.1 (1.1)
 Total cholesterol in mmol/L (SD) 4.8 (1.0) 4.8 (1.0)
 HDL-c in  mmol/L (SD) 1.2 (0.2) 1.3 (0.4)
 LDL-c in mmol/L (SD) 2.6 (0.9) 2.5 (0.9)
Smoking history
 Never smoked, n 10 (44%) 8 (31%)
 Current smoker, n 4 (17%) 5 (19%)
 Ex-smoker, n 9 (39%) 13 (50%)
Concomitant drug use
 Metformin dose in g/day (SD) 2.1 (0.7) 2.0 (0.5)
 Sulfonylurea, n 6 (26%) 8 (31%)
 Insulin, n 15 (65%) 17 (65%)
 Anti-lipidaemic, n 21 (91%) 19 (73%)
 Anti-hypertensive, n 18 (78%) 20 (77%)
LV diastolic function
 E in mL/s (SD) 331 (99) 325 (96)
 A in mL/s (SD) 367 (79) 371 (70)
 E/A ratio (SD) 0.95 (0.44) 0.90 (0.31)
 Edec in mL/s2 × 10−3 (SD) 2.9 (0.9) 2.6 (1.2)
 Ea in cm/s (SD) 6.0 (1.6) 6.0 (1.8)
 E/Ea (SD) 7.3 (2.9) 7.9 (2.3)
LV systolic function
 Stroke volume in mL (SD) 81 (16) 76 (18)
 Ejection fraction in % (SD) 55 (5.8) 55 (4.5)
 Cardiac output in L/min (SD) 5.4 (0.9) 5.5 (1.0)
 Cardiac index in L/min/m2 (SD) 2.5 (0.3) 2.6 (0.4)
 Peak ejection rate in mL/s (SD) 442 (96) 415 (92)
  1. E early transmitral peak flow rate, A late transmitral peak flow rate, Edec peak deceleration of transmitral early peak flow, Ea early peak mitral annular septal tissue velocity
  2. aMacrovascular complications were cerebrovascular or peripheral artery disease and not cardiovascular